Loading...
Market
Which pharmaceutical company will partner to commercialize the Alzheimer's blood test by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Press releases from pharmaceutical companies or business news outlets
Story
Melbourne Researchers Develop Cost-Effective Blood Test to Detect Alzheimer’s Disease for Those Over Age 65
Oct 28, 2024, 01:01 PM
Recent advancements in blood-based biomarkers have shown promise in detecting Alzheimer's disease before symptoms manifest, presenting both clinical and ethical challenges. Researchers at The Florey Institute in Melbourne have developed a simple and cost-effective blood test that can identify Alzheimer's more quickly and accurately. This breakthrough raises important questions about the next steps following a positive result for amyloid plaques and tau tangles. Additionally, researchers in the U.K. and Germany are optimistic about their findings related to Huntington’s disease, which could facilitate early detection and treatment. These developments highlight the growing importance of blood tests for Alzheimer's, particularly for individuals over the age of 65, as the medical community prepares to integrate these tools into clinical practice.
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Yes • 50%
No • 50%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
Kaiser Permanente • 25%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Other • 25%